Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josep V Forment

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Nature Communications|January 10, 2019
ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forksGabriel Balmus, Domenic Pilger, Julia Coates, et al.
Nature Genetics|October 18, 2024
Base editing screens define the genetic landscape of cancer drug resistance mechanismsMatthew A Coelho, Magdalena E Strauss, Alex Watterson, et al.
Cell Reports|May 10, 2023
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cellsAnabel Zelceski, Paola Francica, Lea Lingg, et al.
Plos Genetics|November 21, 2012
Disruption of mouse Cenpj, a regulator of centriole biogenesis, phenocopies Seckel syndromeRebecca E McIntyre, Pavithra Lakshminarasimhan Chavali, Ozama Ismail, et al.
Haematologica|June 6, 2024
Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphomaNicholas Davies, Tegan Francis, Ceri Oldreive, et al.
Nature Communications|August 14, 2023
Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editingSandra Wimberger, Nina Akrap, Mike Firth, et al.
Nature Communications|May 24, 2024
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumoursDiego Dibitetto, Martin Liptay, Francesca Vivalda, et al.
Nature Communications|August 31, 2017
Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancerMohammad Asim, Firas Tarish, Heather I Zecchini, et al.
Genome Medicine|August 26, 2024
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer modelsAndrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, et al.
Cancer Research|April 15, 2022
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient StratificationBenedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop-Guevara, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Nature Communications|January 10, 2019
ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forksGabriel Balmus, Domenic Pilger, Julia Coates, et al.
Nature Genetics|October 18, 2024
Base editing screens define the genetic landscape of cancer drug resistance mechanismsMatthew A Coelho, Magdalena E Strauss, Alex Watterson, et al.
Cell Reports|May 10, 2023
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cellsAnabel Zelceski, Paola Francica, Lea Lingg, et al.
Plos Genetics|November 21, 2012
Disruption of mouse Cenpj, a regulator of centriole biogenesis, phenocopies Seckel syndromeRebecca E McIntyre, Pavithra Lakshminarasimhan Chavali, Ozama Ismail, et al.
Haematologica|June 6, 2024
Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphomaNicholas Davies, Tegan Francis, Ceri Oldreive, et al.
Nature Communications|August 14, 2023
Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editingSandra Wimberger, Nina Akrap, Mike Firth, et al.
Nature Communications|May 24, 2024
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumoursDiego Dibitetto, Martin Liptay, Francesca Vivalda, et al.
Nature Communications|August 31, 2017
Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancerMohammad Asim, Firas Tarish, Heather I Zecchini, et al.
Genome Medicine|August 26, 2024
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer modelsAndrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, et al.
Cancer Research|April 15, 2022
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient StratificationBenedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop-Guevara, et al.
Pageof 5